For the year ending 2025-12-31, SEM had -$33,171K decrease in cash & cash equivalents over the period. $117,242K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 214,533 |
| Distributions from unconsolidated subsidiaries | 52,970 |
| Depreciation and amortization | 140,303 |
| Provision for expected credit losses | 2,362 |
| Equity in earnings of unconsolidated subsidiaries | 54,521 |
| Loss on extinguishment of debt | 0 |
| (gain) loss on sale or disposal of assets | -8 |
| Stock compensation expense | 16,702 |
| Amortization of debt discount, premium and issuance costs | 3,136 |
| Deferred income taxes | 30,652 |
| Accounts receivable | 45,185 |
| Other current assets | -413 |
| Other assets | 8,808 |
| Accounts payable | -854 |
| Accrued expenses | -5,244 |
| Net cash provided by operating activities | 346,467 |
| Business combinations, net of cash acquired | 9,197 |
| Purchases of property, equipment, and other assets | 229,225 |
| Investment in businesses | 1,455 |
| Proceeds from sales and exchanges of assets and sale of business | 23,391 |
| Net cash used in investing activities | -216,486 |
| Borrowings on revolving facilities | 1,290,000 |
| Payments on revolving facilities | 1,295,000 |
| Proceeds from term loans, net of issuance costs | 0 |
| Payments on term loans | 10,500 |
| Payment on senior notes, including call premium | 0 |
| Proceeds from senior notes, net of issuance costs | 0 |
| Borrowings of other debt | 101,218 |
| Principal payments on other debt | 34,328 |
| Dividends paid to common stockholders | 31,435 |
| Repurchase of common stock | 100,077 |
| Decrease in overdrafts | -9,052 |
| Proceeds from issuance of non-controlling interests | 15,904 |
| Distributions to and purchases of non-controlling interests | 89,882 |
| Purchase of membership interests of concentra group holdings parent | 0 |
| Proceeds from concentra initial public offering | 0 |
| Cash transferred to concentra at separation | 0 |
| Net cash used in financing activities | -163,152 |
| Net decrease in cash and cash equivalents | -33,171 |
| Cash and cash equivalents at beginning of period | 59,694 |
| Cash and cash equivalents at end of period | 26,523 |
SELECT MEDICAL HOLDINGS CORP (SEM)
SELECT MEDICAL HOLDINGS CORP (SEM)